Chronopharmacology of intravenous and oral modified release verapamil
- 1 April 1999
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 47 (4) , 413-419
- https://doi.org/10.1046/j.1365-2125.1999.00910.x
Abstract
Aims Using a stable isotope technique which allows simultaneous and differential measuring of orally and intravenously administered drugs we compared the pharmacokinetics and pharmacodynamics of unlabelled modified release verapamil p.o. (steady state) and deuterated verapamil i.v. (single dose) following morning and evening administration.Methods Twelve female and 12 male healthy volunteers were studied in a randomized, crossover design. During the last day of each treatment period (day 6 and day 10) pharmacokinetics and pharmacodynamics (PR interval) of verapamil were assessed; 1 h before ingestion of a new R/S‐verapamil 240 mg modified release formulation (08.00 h vs 20.00 h) a single dose of 10 mg d7‐R/S‐verapamil was administered intravenously. Serum levels of unlabelled and labelled R/S‐verapamil were measured by gas chromatography/mass spectrometry. In selected samples of serum which were chosen at tmin,po and tmax,po the enantiomers were separated by chiral high‐performance liquid chromatography in order to calculate R‐ to S‐verapamil serum concentration ratios.Results We observed no significant differences in pharmacokinetics (AUCpo, Cmax, tmax, CLo, F and R/S enantiomer ratio) between morning and evening treatment with modified release verapamil and there was no influence of time of dosing on mean prolongation of PR interval. AUCiv, CL, Vss and d7‐R/d7‐S enantiomer ratio following verapamil i.v. did not show circadian variation. t1/2 was slightly but statistically significantly increased after the morning infusion. PR‐prolongation was significantly greater after verapamil i.v. in the morning than in the evening. The 90% confidence intervals of the differences between morning and evening administration in AUCpo, Cmax and AUCiv were within the equivalence range of 0.8–1.25.Conclusions Time of dosing has no significant influence on pharmacokinetics and pharmacodynamics of this new modified release formulation of verapamil. Circadian variation in presystemic metabolism of verapamil was not observed.Keywords
This publication has 25 references indexed in Scilit:
- Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil.British Journal of Clinical Pharmacology, 1995
- ChronopharmacokineticsClinical Pharmacokinetics, 1994
- Extrahepatic Metabolism of Drugs in HumansClinical Pharmacokinetics, 1994
- Simultaneous Assessment of the Intravenous and Oral Disposition of the Enantiomers of Racemic Nimodipine by Chiral Stationary- Phase High-Performance Liquid Chromatography and Gas Chromatography/Mass Spectroscopy Combined with a Stable Isotope TechniqueJournal of Pharmaceutical Sciences, 1993
- Circadian Changes of Valproate Kinetics Depending on Meal Condition in HumansThe Journal of Clinical Pharmacology, 1992
- Chronopharmacokinetics and Cardiovascular Effects of NifedipineChronobiology International, 1991
- Pharmacokinetic Drug Interactions with Oral ContraceptivesClinical Pharmacokinetics, 1990
- Differences in Oral Verapamil Absorption as a Function of Time of DayThe Journal of Clinical Pharmacology, 1989
- The effect of age upon liver volume and apparent liver blood flow in healthy manHepatology, 1989
- The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humansAmerican Heart Journal, 1985